Preclinical studies on new proteins as carrier for glycoconjugate vaccines
نویسندگان
چکیده
منابع مشابه
Preclinical and clinical safety studies on DNA vaccines.
DNA vaccines are based on the transfer of genetic material, encoding an antigen, to the cells of the vaccine recipient. Despite high expectations of DNA vaccines as a result of promising preclinical data their clinical utility remains unproven. However, much data is gathered in preclinical and clinical studies about the safety of DNA vaccines. Here we review current knowledge about the safety o...
متن کاملSTUDIES ON HEPATITIS B VACCINES
HBs vaccines were prepared by three different methods: 1) Heat inactivation (Krugman, et.al 1971)2) Ammonium sulphate precipitation followed by column chromatography (Sephadex G-200) 3) PEG-6000 (polyethylene glycol) precipitation followed by column chromatography using Sephadex G-200. Their efficacy was studied in guinea pigs, and the results compared with commercial Japanese vaccine (Gr...
متن کاملPerspectives on clinical and preclinical testing of new tuberculosis vaccines.
This review hopes to improve the selection of new tuberculosis (TB) vaccines by providing several perspectives on the immunization of humans, mice, guinea pigs, rabbits, and monkeys which have not usually been considered. (i) In human TB vaccine trials, the low rate of healing of Mycobacterium bovis BCG lesions (used as the control group) would distinguish individuals who might be helped by vac...
متن کاملPreclinical studies of 166Ho-chitosan for treatment of hepatocellular carcinoma
Introduction: Recently, due to the special characteristics of 166Ho and chitosan, 166Ho-chitosan complex was developed for treatment of tumors such as hepatocellular carcinoma. This complex has been lately prepared with high radiochemical purity in our lab. The preclinical studies of the complex however should be performed to evaluate the tracer concentration in target and...
متن کاملCross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites
Production of glycoconjugate vaccines involves the chemical conjugation of glycans to an immunogenic carrier protein such as Cross-Reactive-Material-197 (CRM197). Instead of using glycans from natural sources recent vaccine development has been focusing on the use of synthetically defined minimal epitopes. While the glycan is structurally defined, the attachment sites on the protein are not. Fu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Vaccine
سال: 2016
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2016.06.039